Indian Pharma Largely Protected from Trump's 100% Tariffs on Imported Drugs

Sep 26, 2025 04:11 pm CST

President Trump's new 100% tariffs on imported branded pharmaceuticals may have minimal impact on India's drug industry as most major Indian pharma companies already operate manufacturing facilities in the US. With Indian exports to America primarily consisting of generic medications worth $10.5 billion annually, companies like Cipla, Dr Reddy's, and Biocon are strategically positioned to navigate these trade restrictions while stock markets respond cautiously to the announcement.